Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the acute intermittent porphyria market size evolved in recent years?

The acute intermittent porphyria market has experienced steady growth, with projections showing an increase from $4.37 billion in 2024 to $4.66 billion in 2025 at a CAGR of 6.7%. The historical expansion has been driven by rising healthcare expenditures, the growing biopharmaceuticals market, increased prevalence of genetic disorders, the expansion of telemedicine services, and a heightened focus on early disease detection.

What are the predictions for the acute intermittent porphyria market size in the coming years?

The acute intermittent porphyria market is projected to witness strong growth, reaching $5.96 billion in 2029 with a CAGR of 6.3%. Growth factors include rising cases of acute intermittent porphyria, increased awareness of rare diseases, supportive government policies, growing patient advocacy, and expanded access to genetic testing. Key trends include advancements in diagnostics, novel therapeutic developments, increased R&D investment, pharmaceutical collaborations, and technological innovations in treatment.

Get your acute intermittent porphyria market report here!

https://www.thebusinessresearchcompany.com/report/acute-intermittent-porphyria-global-market-report

What key factors are fueling the growth of the acute intermittent porphyria market?

The increasing prevalence of metabolic disorders is expected to drive the acute intermittent porphyria market. These disorders result from abnormal metabolic reactions caused by genetic and lifestyle factors. Pharmaceutical investments in rare disease treatments are rising due to increased diagnosis rates. For instance, in December 2023, Cleveland Clinic reported that inherited metabolic disorders affect approximately 1 in 1,000 to 2,500 births worldwide. Therefore, the rising prevalence of metabolic disorders is accelerating the acute intermittent porphyria market.

How is the global acute intermittent porphyria market divided into key segments?

The acute intermittent porphyriamarket covered in this report is segmented –

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments

3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

Who are the key firms paving the way for growth in the acute intermittent porphyria market?

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Which trends are expected to transform the acute intermittent porphyria market?

Major companies in the acute intermittent porphyria market are focusing on innovative treatment options, such as acute intermittent porphyria management tablets, to improve patient care. These tablets are oral medications used to manage or prevent the symptoms and acute attacks associated with AIP. For example, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. These tablets are primarily used to manage psychotic disorders and schizophrenia, control nausea and vomiting, and alleviate pre-surgical anxiety. Additionally, they assist in treating acute intermittent porphyria, managing manic symptoms of manic-depressive illness, and controlling intractable hiccups.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19264

What regions are contributing significantly to the growth of the acute intermittent porphyria market?

North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Acute Coronary Syndrome Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Acute Ischemic Stroke Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Acute Pancreatitis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: